<?xml version="1.0" encoding="UTF-8"?>
<p>Remarkably, antiviral drugs already experimented for CoV infections can potentially treat COVID-19. The use of HIV protease inhibitor lopinavir in association with ritonavir in recent Chinese trials on SARS-CoV2 patients requires further evaluation and investigation [
 <xref rid="B55-ijms-21-05145" ref-type="bibr">55</xref>,
 <xref rid="B56-ijms-21-05145" ref-type="bibr">56</xref>]. These antiviral molecules are of known pharmacokinetic and pharmacodynamic properties, dosing regimens, stability, and adverse effects and are easily available [
 <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>,
 <xref rid="B20-ijms-21-05145" ref-type="bibr">20</xref>].
</p>
